Novel therapies to treat muscle wasting in cancer

Grant number: 1041865 | Funding period: 2013 - 2016

Completed

Abstract

Cancer cachexia is a devastating disease characterised by muscle wasting, weakness and fatigue. It impairs patient quality of life and accounts for >20% of cancer-related deaths. This project will identify factors responsible for cancer cachexia and develop new strategies to alleviate wasting and weakness in cancer patients, to improve their quality of life and reduce mortality.

Related publications (4)

Mechanisms of chemotherapy‐induced muscle wasting in mice with cancer cachexia

Kate T Murphy, Kristy Swiderski, James G Ryall, Jonathan R Davey, Hongwei Qian, Séverine Lamon, Victoria C Foletta, Jennifer Trieu, Annabel Chee, Suzannah J Read, Timur Naim, Paul Gregorevic, Gordon S Lynch

Murine models of Duchenne muscular dystrophy: is there a best model?

Kristy Swiderski, Gordon S Lynch

2021-08-01

N/A.

Phosphorylation of ERK and dystrophin S3059 protects against inflammation-associated C2C12 myotube atrophy

Kristy Swiderski, Christopher J Brock, Jennifer Trieu, Annabel Chee, Savant S Thakur, Dale M Baum, Paul Gregorevic, Kate T Murphy, Gordon S Lynch

2021-04-01

The dystrophin-glycoprotein complex (DGC) is a multiprotein structure required to maintain muscle fiber membrane integrity, transm..

Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer

Kate T Murphy, Mohammed I Hossain, Kristy Swiderski, Annabel Chee, Timur Naim, Jennifer Trieu, Vanessa Haynes, Suzannah J Read, David I Stapleton, Sarah M Judge, Jose G Trevino, Andrew R Judge, Gordon S Lynch

2019-02-15

Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass associated with significa..